DFVX vs EMR

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for DFVX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 20 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 28 cases where DFVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

DFVX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for DFVX crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where DFVX advanced for three days, in 194 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

DFVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 223 of 273 cases where DFVX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 219 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

The Aroon Indicator entered an Uptrend today. In 156 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.

Bearish Trend Analysis

The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 20 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 60 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.444) is normal, around the industry mean (3.843). P/E Ratio (35.370) is within average values for comparable stocks, (36.971). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.032) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (189.487).